Literature DB >> 29896223

Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

Celia N Sanchez-Dominguez1, Hugo L Gallardo-Blanco2, Mauricio A Salinas-Santander3, Rocio Ortiz-Lopez4.   

Abstract

Biotransformation is an enzyme-catalyzed process in which the body converts endogenous compounds, xenobiotics and toxic substances into harmless or easily excreted metabolites. The biotransformation reactions are classified as phase I and II reactions. Uridine 5'-diphospho (UDP)-glucuronosyltransferases (UGTs) are a superfamily of phase II enzymes which have roles in the conjugation of xenobiotics or endogenous compounds, including drugs and bilirubin, with glucuronic acid to make them easier to excrete. The method the human body uses to achieve glucuronidation may be affected by a large interindividual variation due to changes in the sequences of the genes encoding these enzymes. In the last five years, the study of the genetic variants of the UGTs at a molecular level has become important due to its association with several diseases and the ability to predict adverse events due to drug metabolism. In the present review, the structure and the prominent genetic variants of the UGT1A subfamily and their metabolic and clinical implications are described.

Entities:  

Keywords:  UGT1A1*1; UGT1A1*28; pharmacogenomics; uridine 5′-diphospho-glucuronosyltransferases

Year:  2018        PMID: 29896223      PMCID: PMC5995049          DOI: 10.3892/etm.2018.6184

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  94 in total

1.  Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.

Authors:  Wan Beom Park; Pyoeng Gyun Choe; Kyoung-Ho Song; Jae Hyun Jeon; Sang Won Park; Hong Bin Kim; Nam Joong Kim; Myoung-Don Oh; Kang Won Choe
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

2.  [Crigler-Najjar syndrome: diagnosis and treatment].

Authors:  B Lodoso Torrecilla; E Palomo Atance; C Camarena Grande; Maria C Díaz Fernández; L Hierro Llanillo; A De la Vega Bueno; E Frauca Remacha; G Muñoz Bartolo; P Jara Vega
Journal:  An Pediatr (Barc)       Date:  2006-07       Impact factor: 1.500

3.  Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice.

Authors:  Yoshihiro Maruo; Yoriko Morioka; Hiroshi Fujito; Sayuri Nakahara; Takahide Yanagi; Katsuyuki Matsui; Asami Mori; Hiroshi Sato; Robert H Tukey; Yoshihiro Takeuchi
Journal:  J Pediatr       Date:  2014-03-17       Impact factor: 4.406

4.  Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.

Authors:  Ebrahim Eskandari-Nasab; Mohammad Hashemi; Hamzeh Rezaei; Aliakbar Fazaeli; Mohammad Ali Mashhadi; Simin Sargholzaei Moghaddam; Farshid Arbabi; Mahdi Jahantigh; Mohsen Taheri
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

Review 5.  Nanoparticles vs cancer: a multifuncional tool.

Authors:  Celia N Sanchez-Dominguez; Hugo L Gallardo-Blanco; Arturo A Rodriguez-Rodriguez; Andrea V Vela-Gonzalez; Margarita Sanchez-Dominguez
Journal:  Curr Top Med Chem       Date:  2014-03       Impact factor: 3.295

6.  Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.

Authors:  Taroh Satoh; Takashi Ura; Yasuhide Yamada; Kentaro Yamazaki; Toshimasa Tsujinaka; Masaki Munakata; Tomohiro Nishina; Shu Okamura; Taito Esaki; Yasutsuna Sasaki; Wasaburo Koizumi; Yoshihiro Kakeji; Naoki Ishizuka; Ichinosuke Hyodo; Yuh Sakata
Journal:  Cancer Sci       Date:  2011-08-12       Impact factor: 6.716

Review 7.  Modulation of UDP-glucuronosyltransferase activity by endogenous compounds.

Authors:  Yuji Ishii; Arief Nurrochmad; Hideyuki Yamada
Journal:  Drug Metab Pharmacokinet       Date:  2010       Impact factor: 3.614

8.  Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer.

Authors:  C P Strassburg; A Vogel; S Kneip; R H Tukey; M P Manns
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

9.  Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Authors:  E Beutler; T Gelbart; A Demina
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.

Authors:  Chen Yang; Ying Liu; Wen-qi Xi; Chen-fei Zhou; Jin-ling Jiang; Tao Ma; Zheng-bao Ye; Jun Zhang; Zheng-gang Zhu
Journal:  Drug Des Devel Ther       Date:  2015-07-17       Impact factor: 4.162

View more
  6 in total

1.  Plant terpenoid metabolism co-opts a component of the cell wall biosynthesis machinery.

Authors:  Adam Jozwiak; Prashant D Sonawane; Sayantan Panda; Constantine Garagounis; Kalliope K Papadopoulou; Bekele Abebie; Hassan Massalha; Efrat Almekias-Siegl; Tali Scherf; Asaph Aharoni
Journal:  Nat Chem Biol       Date:  2020-05-18       Impact factor: 15.040

2.  UGT1A1 and UGT1A9 Are Responsible for Phase II Metabolism of Tectorigenin and Irigenin In Vitro.

Authors:  Ji Li; Zhangyao Xu; Jifeng Gu
Journal:  Molecules       Date:  2022-06-26       Impact factor: 4.927

Review 3.  Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.

Authors:  Tingyu Wang; Yitian Zhou; Guosheng Cao
Journal:  Eur J Clin Pharmacol       Date:  2021-01-29       Impact factor: 2.953

4.  Genetic testing of UGT1A1 in the diagnosis of Gilbert syndrome: The discovery of seven novel variants in the Chinese population.

Authors:  Leilei Gu; Yue Han; Donghua Zhang; Qiming Gong; Xinxin Zhang
Journal:  Mol Genet Genomic Med       Date:  2022-04-14       Impact factor: 2.473

5.  Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.

Authors:  Shekman Wong; Cecile Krejsa; Dana Lee; Anna Harris; Emilie Simard; Xiaohui Wang; Martine Allard; Terry Podoll; Terry O'Reilly; J Greg Slatter
Journal:  Clin Pharmacol Drug Dev       Date:  2022-02-16

Review 6.  Pharmacogenetics of Statin-Induced Myotoxicity.

Authors:  Ping Siu Kee; Paul Ken Leong Chin; Martin A Kennedy; Simran D S Maggo
Journal:  Front Genet       Date:  2020-10-16       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.